Suppression of Drug Resistance in Dengue Virus
ABSTRACT Dengue virus is a major human pathogen responsible for 400 million infections yearly. As with other RNA viruses, daunting challenges to antiviral design exist due to the high error rates of RNA-dependent RNA synthesis. Indeed, treatment of dengue virus infection with a nucleoside analog res...
Enregistré dans:
Auteurs principaux: | Roberto Mateo, Claude M. Nagamine, Karla Kirkegaard |
---|---|
Format: | article |
Langue: | EN |
Publié: |
American Society for Microbiology
2015
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fca0a1a02dcf4272b992bde8f4d1ca32 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity
par: Jasmine Moshiri, et autres
Publié: (2020) -
Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus
par: J. A. Swanstrom, et autres
Publié: (2016) -
Dengue Virus Genome Uncoating Requires Ubiquitination
par: Laura A. Byk, et autres
Publié: (2016) -
Role of Complement in Dengue Virus Infection: Protection or Pathogenesis?
par: Sujan Shresta
Publié: (2012) -
Complement-Mediated Neutralization of Dengue Virus Requires Mannose-Binding Lectin
par: Panisadee Avirutnan, et autres
Publié: (2011)